• isi_ọkọlọtọ_01

Ntụle ahịa nke Dulaglutide, Liraglutide na Semaglutide.

Nnukwu ọgwụ Lilly, ụlọ ọrụ America na Novo Nordisk, ụlọ ọrụ Danish, ekwupụtala nke ọma data ahịa nke isi ngwaahịa ha na 2020: Dulaglutide abụrụla ọgwụ TOP1 GLP-1, yana ire $ 5.07Bn na 2020, otu afọ- na-abawanye na 22.8%;Liraglutide Malite ịbanye n'oge mgbada, ahịa na 2020 si na $ 4.14Bn gaa $ 3.93Bn, mbelata afọ na afọ nke 5.1%;semaglutide tolitere ngwa ngwa, yana ire ere ruru $ 3.72Bn na 2020, mmụba otu afọ na 119.9%.

Ewepụtara Lilly's dulaglutide (aha ahia Trulicity®) na 2014 wee bụrụ ọgwụ mgbochi na-ere $5.07Bn n'ime naanị afọ 6, ghọrọ onye mmeri ahịa nke ọgwụ GLP-1.Otu ngwaahịa Novo Nordisk akwụsịla n'azụ Lilly nwa oge.Liraglutide ya (aha ahia Victoza® na Saxenda®), nke ewepụtara na 2009, bụbu onye mmeri ahịa nke ọgwụ GLP-1, ọnụ ahịa ya kacha elu na 2017 ruru $ 4.37bn, n'agbanyeghị na enwere ihe ngosi abụọ maka ụdị ọrịa shuga II na oke ibu. , data maka 2020 na-egosi na ahịa ọgwụ a abanyela n'oge ọdịda.Otu Novo Nordisk's semaglutide (aha ahia Ozempic® na Rybelsus®) etoola ngwa ngwa wee ghọọ ọgwụ mgbochi ọzọ na-ere $3.72Bn n'ime afọ atọ.Ọgwụ ahụ nwere ụdị ọgwụgwọ abụọ nke ịgba ọgwụ mgbochi na nkwadebe ọnụ.

Site na mpaghara ala, United States bụ isi obodo liraglutide na-ere ahịa, na-aza ihe fọrọ nke nta ka ọ bụrụ 60% na 2020, mbelata kwa afọ nke 11.02%;ọ bụkwa nlaazu na United States butere mbelata n'ahịa zuru ụwa ọnụ maka liraglutide.Mpaghara EMEA (Europe, Middle East, Africa) etolitela nwayọ, yana CAGR nke naanị 1.6% n'ime afọ ise gara aga;China bụ ahịa na-eto ngwa ngwa, na-ere $ 182.50Mn na 2020, yana ọnụego uto kwa afọ nke 42.39%.Ebe ọ bụ na semaglutide nọ n'ahịa n'oge na-adịghị anya, ahịa niile nọ n'ọkwa nke uto ngwa ngwa.United States ka bụ ahịa kachasị ukwuu, na-aza 80.04% nke ahịa na 2020, mmụba kwa afọ nke 106.08%;EMEA nwere naanị 13.64% òkè mana ọnụego uto afọ na afọ nke 249.65% %.Emere Semaglutide na China na 2020 na ire nke $ 1.61Mn.Ihe onyonyo 3 na-egosi ọnọdụ mpaghara dulaglutide.Dị ka nnukwu ahịa, United States nwere ahịa dị elu dị ka $ 3.836Bn, na-aza 75.69%, yana ọnụ ọgụgụ na-eto eto kwa afọ nke 79.18%.

Ikikere isi maka liraglutide (Victoza® na Saxenda®) agwụla na China ma na-achọ ịkubie ume na US, Japan na Germany.Edobela ọgụ patent Teva na Novo Nordisk, ụdị ụdị Teva ga-adị na 2023. Mylan debakwara ngwa ANDA na FDA maka liraglutide na nkwupụta PIV.Site na njedebe nke nta nke nta nke akwụkwọ ikike ikike na egwu nke ndị na-emepụta ọgwụ na-emepụta ọgwụ, ọgwụ ahụ ga-eji nwayọọ nwayọọ na-abanye n'oge nkwụsị.Patent nke US nke Trulicity® agaghị agwụ ruo 2027, ebe ikike ikike ikike nke mba ndị isi Europe na Japan agaghị agwụ ruo 2029, na isi nchedo patent dị ogologo karịa nke liraglutide.Isi ikike ikike nke semaglutide (Ozempic® na Rybelsus®) ga-ekubi ume na 2032 na nke kachasị ọhụrụ, ma a ka nwere nnukwu ohere maka uto ahịa, mana oge ngwụcha ya na China bụ 2026.

nwere

 


Oge nzipu: Jul-25-2022